Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 17,392 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 17,392 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total transaction of $315,838.72. Following the sale, the chief operating officer owned 205,141 shares in the company, valued at $3,725,360.56. This trade represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80.
• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total transaction of $2,684.98.
• On Monday, December 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00.

Bicara Therapeutics Price Performance

NASDAQ BCAX traded down $0.04 on Thursday, reaching $18.50. The company had a trading volume of 950,200 shares, compared to its average volume of 516,872. The company’s fifty day moving average is $16.43 and its 200-day moving average is $15.70. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $19.71.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC purchased a new position in Bicara Therapeutics during the third quarter worth about $481,000. Artisan Partners Limited Partnership purchased a new stake in Bicara Therapeutics in the second quarter valued at approximately $3,742,000. Skandinaviska Enskilda Banken AB publ boosted its stake in shares of Bicara Therapeutics by 160.9% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock valued at $922,000 after purchasing an additional 61,201 shares during the period. Schroder Investment Management Group grew its holdings in shares of Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock worth $3,951,000 after purchasing an additional 383,681 shares during the last quarter. Finally, SCS Capital Management LLC bought a new position in shares of Bicara Therapeutics in the second quarter worth approximately $496,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BCAX shares. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citizens Jmp began coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They issued a “market perform” rating and a $31.00 price objective for the company. Finally, Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 11th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.33.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.